RT Journal Article
T1 Ocular surface toxicity of depatuxizumab mafoditin (ABT-414): case reports.
A1 Rocha-de-Lossada, Carlos
A1 Linero, Carmen Alba
A1 Santos-Ortega, Alvaro
A1 Rodriguez-Calvo-de-Mora, Marina
A1 Rachwani, Rahul
A1 Borroni, Davide
A1 Alba, Emilio
A1 Benavides-Orgaz, Manuel
A1 Romano, Vito
K1 Glioblastoma/drug therapy
K1 Antibodies, monoclonal, humanized/therapeutic use
K1 Cornea/drug effects
K1 Visual disorders/etiology
K1 Case reports
AB The purpose of this study is to report the clinical features and outcomes of ocular surface toxicity following depatuxizumab mafoditin (ABT-414) therapy for unresectable glioblastoma. Ocular signs and symptoms of three patients treated with ABT-414 during a phase III trial for glioblastoma multiforme were evaluated. Both eyes of all patients were damaged during the week after the first infusion of the ABT-414 molecule. In all patients, mild-to-moderate keratitis could be ascertained, along with decreased visual acuity and blurred vision, as well as foreign-body sensation and redness. Symptoms and visual acuity improved 4 weeks. In conclusion, ABT-414 therapy may cause transient ocular surface toxicity. The initiation of artificial tears and lubricant ointment was enough to control the ocular surface signs and symptoms. A multidisciplinary approach, complete ophthalmologic monitorization, and elaboration of protocols are required to adequately manage these patients.
PB Belfort Editora
YR 2021
FD 2021-02-09
LK http://hdl.handle.net/10668/21667
UL http://hdl.handle.net/10668/21667
LA en
NO Rocha-de-Lossada C, Linero CA, Ortega ÁS, Calvo-de-Mora MR, Rachwani R, Borroni D, et al. Ocular surface toxicity of depatuxizumab mafoditin (ABT-414): case reports. Arq Bras Oftalmol. 2021 Sep 10;85(4):411-414
DS RISalud
RD Jun 1, 2025